Theromics

Theromics is pioneering a protein-based nanopolymer platform that acts as a thermal accelerant for soft tissue ablation and targeted drug delivery. Its core technology addresses key limitations in current ablation techniques, such as heat-sink effects and irregular ablation zones, aiming to reduce the 30% recurrence rate. The platform also enables Thermally Activated Combination Therapy (TACT), which localizes therapeutics to minimize systemic side effects. The company is initially targeting applications in oncology and women's health, specifically uterine fibroids.

Injectable, protein-based nanopolymer gels (HeatSYNC™, CryoSYNC) that act as thermal accelerants to enhance energy transfer during tissue ablation. The platform mitigates heat-sink effects, creates larger/more spherical ablation zones, and can be used for localized drug delivery (TACT - Thermally Activated Combination Therapy).

Theromics competes with companies developing improved ablation devices (e.g., Medtronic, Boston Scientific, Johnson & Johnson) but its gel is positioned as a complementary enhancer for all modalities. In drug delivery, it faces competition from other localized delivery platforms (e.g., nanoparticles, embolics). Its unique angle is the direct synergy with thermal ablation energy.